Fintel reports that on August 16, 2023, HC Wainwright & Co. maintained coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a Buy recommendation.
Analyst Price Forecast Suggests 517.37% Upside
As of August 2, 2023, the average one-year price target for Unicycive Therapeutics is 4.69. The forecasts range from a low of 3.03 to a high of $7.35. The average price target represents an increase of 517.37% from its latest reported closing price of 0.76.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Unicycive Therapeutics is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.14.
What is the Fund Sentiment?
There are 22 funds or institutions reporting positions in Unicycive Therapeutics. This is an increase of 5 owner(s) or 29.41% in the last quarter. Average portfolio weight of all funds dedicated to UNCY is 0.01%, an increase of 5.94%. Total shares owned by institutions increased in the last three months by 124.23% to 1,830K shares.
What are Other Shareholders Doing?
Balyasny Asset Management holds 717K shares representing 4.71% ownership of the company.
Nantahala Capital Management holds 647K shares representing 4.25% ownership of the company. No change in the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 115K shares representing 0.76% ownership of the company.
Goldman Sachs Group holds 96K shares representing 0.63% ownership of the company.
Geode Capital Management holds 96K shares representing 0.63% ownership of the company. In it's prior filing, the firm reported owning 26K shares, representing an increase of 72.77%. The firm increased its portfolio allocation in UNCY by 1,333.42% over the last quarter.
Unicycive Therapeutics Background Information
(This description is provided by the company.)
Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
Additional reading:
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
